Repeat offender: Huntington’s and the DNA repair clock

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Latus Bio‘s Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.

Huntington‘s disease is usually told as a story of inheritance; a child is born with too many CAG repeats in the huntingtin gene, and the rest is fate. That is only half the plot. In the brain‘s medium spiny neurons (MSNs), those repeats keep lengthening across a lifetime – a slow stutter in DNA mismatch repair – and it is this somatic expansion, rather than the inherited count alone, that increasingly looks like the clock setting the pace of disease.

Latus Bio has now published a paper in Nature Communications that tries to read the dial. Built from human natural history and neuronal expansion data, its computational model simulates the long-term effect of suppressing MSH3, the mismatch repair protein that drives the expansion; the company pairs it with preclinical data on LTS-201, an AAV gene therapy designed to do just that. Can a model built on human data stand in for decades of follow-up? And what does a monogenic brain disease have to say about aging?

Longevity.Technology: Huntington‘s sits outside our usual remit, and LTS-201 is a rare-disease program yet to reach the clinic; nobody should mistake it for an aging therapy. The mechanism is another matter. Somatic instability is genomic instability with its sleeves rolled up – a hallmark of aging playing out in one gene, in one population of neurons, over decades – and it offers geroscience something it rarely gets: a clean causal line from DNA repair to clinical decline. The modeling is the part to watch. Aging interventions share Huntington‘s awkward arithmetic; the payoff arrives long after the dose, and no trial runs that long. A framework that converts target engagement into “years of delay” is the sort of bridge the field needs – although in one simulated patient, its projections run to a 126% reduction in decline at three years, which, taken literally, implies improvement rather than merely holding steady. Until human data arrive, it remains a bridge drawn on paper.

The study – funded by Latus and led by Jang-Ho Cha of Latus and Beverly Davidson, the company’s cofounder, of Children’s Hospital of Philadelphia – builds on earlier modeling of repeat expansion in single neurons; it links the depth of MSH3 knockdown and the proportion of MSNs reached to projected delays in progression across a range of inherited repeat lengths and ages of intervention. One finding runs against intuition: deep knockdown in fewer neurons outperforms shallow knockdown in many. By the authors’ reckoning, halving MSH3 in half the MSNs should delay motor onset by at least five years for a wide swath of patients; earlier intervention pays best, with benefit the model measures in decades. The code is open, and the framework is modality-agnostic – as applicable to antisense oligonucleotides or small molecules as to gene therapy [1].

In nonhuman primates, LTS-201 – which pairs Latus’s engineered AAV-DB-3 capsid with an artificial microRNA – cut MSH3 mRNA in striatal MSNs by 48%, 65% and 94% at low, mid and high doses; fed back into the model, even the lowest cleared the authors’ five-year threshold. The caveats are worth stating: the primate study ran for four weeks with two animals per dose, and reductions measured in bulk tissue were considerably smaller. In HdhQ111 mice, the therapy reduced striatal somatic instability by up to 46% [1]. The approach is designed to leave wild-type huntingtin untouched, sidestepping huntingtin-lowering strategies whose record has been mixed – although the authors suggest the two might yet work best in tandem. Latus still describes LTS-201 as preclinical, having earlier said it aimed to file an IND in the third quarter of this year.

It is in the discussion that the paper drifts closest to geroscience. If somatic instability can be slowed before it tips neurons into dysfunction, the authors argue, treatment could move from symptomatic patients to presymptomatic carriers – a preventive gene therapy paradigm, in which the aim is not to repair damage but to stop it accruing. That is geroscience’s own wager, writ small. And because somatic expansion is also measurable in blood, where it has been linked to biomarkers of neurodegeneration long before motor diagnosis, Huntington’s offers something aging research is still searching for: an early readout tied directly to mechanism [1].

The framework could, the paper notes, extend to X-linked dystonia-parkinsonism and myotonic dystrophy type 1, where MSH3 has also been implicated as a disease modifier – provided expansion-rate data for those repeats and cell types become available [1]. Nor is MSH3 alone in the dock; PMS1 and FAN1 are already under scrutiny. If the model holds, Huntington’s may end up teaching aging research how to count the years it cannot afford to wait for.


Wondering which biotechs are targeting genomic instability? Ask DLT to “show me companies developing therapies that target DNA repair pathways” or to “identify longevity biotechs working on somatic mutation and genomic instability” – explore the platform HERE.

[1] https://www.nature.com/articles/s41467-026-78769-2

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE